Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.6.3.14 (
ATP synthase
)
7,042
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Mitochondria produce energy through oxidative phosphorylation. A key enzyme in this pathway is F0F1-
ATP synthase
, catalyzing ATP production from ADP and inorganic phosphate. Recently a subunit of F0F1-
ATP synthase
, oligomycin sensitivity-conferring protein, was identified as a new estradiol-binding protein. Estradiol could directly modulate mitochondrial
ATP synthase
activity through this subunit. In addition, intracellular ATP levels play a role in apoptotic death, which is an energy-dependent process requiring functioning mitochondria. Here we examined the effect of 17 beta-estradiol on F0F1-
ATP synthase
directly (in permeabilized cells) and in intact osteoclastic
FLG
29.1 cells, a model of inducible apoptosis. The baseline F0F1-
ATP synthase
activity of
FLG
29.1 cells was 4.485 nmol/min per mg. Estradiol rapidly inhibited F0F1-
ATP synthase
activity in the physiological range (half-inhibition concentration, IC50, of 30 nmol/l). With 1 nmol/l of estradiol, the inhibition was already significant (8-10% inhibition, p < 0.01) and with 100 nmol/l residual enzyme activity was only 15% (85% inhibition, p < 0.01). In addition, the effect of estradiol appeared to be directed towards F0F1-
ATP synthase
, since succinate-sustained respiration, uncoupled from the electron transport chain, was unaffected by estradiol. We assayed F0F1-
ATP synthase
activity in
FLG
29.1 cells during inducible apoptosis. No significant difference of ATP synthesis was detected in apoptotic cells versus controls. In conclusion, we showed a new non-genomic effect of estradiol on a key mitochondrial enzyme, which thereby directly modulates cellular energy metabolism.
...
PMID:Dose-dependent inhibition of mitochondrial ATP synthase by 17 beta-estradiol. 1258 31